HOME> お知らせ> T&T Scientific社バーチャルイベントのお知らせ
(脂質ナノ粒子および非ウイルス性ナノキャリアについての国際カンファレンス)

T&T Scientific社バーチャルイベントのお知らせ
(脂質ナノ粒子および非ウイルス性ナノキャリアについての国際カンファレンス)

掲載日情報:2021/07/06 現在Webページ番号:68192

T&T Scientific社は,脂質ナノ粒子などの作製に用いる装置・器具・試薬を取り扱っているメーカーです。
この度,8月5日(木)~7日(土)に,有料のバーチャルイベント『脂質ナノ粒子および非ウイルス性ナノキャリアについての国際カンファレンス』を開催することとなりました。現在,急拡大をしているナノ粒子ドラッグデリバリーの分野におけるすべてを明確にするため,学術界・産業界の双方から演者を集めました。
夜中の遅い時間となりますが,ぜひご参加いただき,皆様のご研究にお役立て下さい。
リポソーム作製カートリッジ:NanoSizer Extrusion Kitの詳細についてはこちらをご覧下さい。


脂質ナノ粒子カンファレンスのロゴ

CRISPR-Cas9の登場やCOVID-19(新型コロナウイルス)の流行により,脂質を用いた製剤は,様々な疾患を治療するための治療薬における開発対象となりました。脂質ナノ粒子(LNP)がオリゴヌクレオチドや低分子などにおける標準のドラッグデリバリー担体として適用可能であることは,製薬業界の展望に大きな変化をもたらしました。リポソーム製剤は,ひとりの患者を対象とした個別化医療のような小さな患者サイズから,世界規模のワクチンまで,人類にその恩恵を十分に提供し始めたばかりです。

本カンファレンスは,脂質ベース,無機物,高分子のナノ粒子,およびmRNA,RNAiについてネットワークを広げ,より多くのことを学びたいと考えているあらゆるプロフェッショナルのために開催されます。


イベント概要

  • イベント名:Global Conference for Lipid Nanoparticles & Other Non-viral Nanocarriers
  • 開催日:2021年8月5日(木)~7日(土),12:00 am ~ 7:00 am(3日間とも,日本時間)
  • 配信方法:Microsoft Teams Webinar Platform
  • 参加費:1日のみ参加:$100,3日間参加:$240(7月6日現在)
  • 登録方法:T&T Scientific社Webにて参加登録を行って下さい。

参加費,登録方法などについてはT&T Scientific社Webの記載をご確認の上,参加登録を行って下さい。
すべての発表において,日本語への同時通訳を予定しています。
3日間すべてご登録・ご参加をされた方には,後日,修了証書(Certificate of Completion)をお送りいたします。


各日のテーマ

  • 一日目:8月5日(木):Non-viral Drug Delivery Systems for Variety of Active Pharmaceutical Ingredients
  • 二日目:8月6日(金):Drug Delivery Systems Complexed with Active Pharmaceutical Ingredients
  • 三日目:8月7日(土):Clinical and Commercial Manufacturing Applications of Non-viral Based Nanoparticle Vaccines and Therapeutics

トピックス

  • Non-viral Delivery Formulation Technologies
  • Analytical Methods for Non-viral Nanomedicines
  • Manufacturing Processes for Non-viral Nanomedicines
  • Novel Non-viral Drug Delivery Systems
  • Quality Assurance(QA)
  • Supply Chain Logistics
  • Supply, Demand, and Capacities, and Investments
  • Plus more broad topics in digital, automated and AI in healthcare and life science

タイムテーブル(3日間共通)

記載の時間はすべて日本時間。
詳細なプログラムおよび演者略歴についてはこちらをご覧下さい。

  • 12:00 am ~ 1:00 am : Keynote Speech(基調講演,15分間のQ&Aを含む)
  • 1:00 am ~ 6:30 am : シンポジウム
    各セッション:30分(5~10分間のQ&Aを含む)
  • 6:30 am ~ 7:00 am : バーチャルレセプション

目次に戻る

イベント紹介の動画

国際カンファレンスのプレビュー(英語版,約2分)

T&T Scientific Universityの概要(英語版,約1分)



目次に戻る

Keynote Speech(基調講演)

各日ともイベント冒頭(12:00 am ~ 1:00 am,日本時間)に,Keynote Speech(基調講演)を行います(15分間のQ&Aを含む)。

日 付演 者
(所 属)
演 題
一日目
8月5日(木)
Dr. Gaurav SahayDr. Gaurav Sahay
(Associate Professor at the Oregon State University)
Lipid Nanoparticle mRNA Vaccine and Therapeutic Formulation Technologies
二日目
8月6日(金)
Dr. Michael McCamanDr. Michael McCaman
(Senior Consultant at BioProcess Technology Consultants:BDO)
Lipid Nanoparticle Gene Therapies and Vaccines: from Development to Manufacturing
三日目
8月7日(土)
Mr. Greg TroianoMr. Greg Troiano
(Chief Manufacturing Officer at Translate Bio)
Overcoming Challenges of Clinical and Commercial Supply Chain for Complex Nanoparticle Formulations

目次に戻る

詳細プログラムおよび演者について

一日目:8月5日(木)プログラム

テーマ:Non-viral Drug Delivery Systems for Variety of Active Pharmaceutical Ingredients

時 刻
(日本時間)
演 者
(所 属)
演 題
12:00 am ~ 1:00 am
(Keynote Speech:基調講演)
Dr. Gaurav Sahay
(Oregon State University)
Lipid Nanoparticle mRNA Vaccine and Therapeutic Formulation Technologies: the Present and the Future
1:30 am ~ 2:00 amDr. Richard (Trey) Fisher
(T&T Scientific Corporation)
Critical Attributes of RNA Therapeutics and Vaccines
2:00 am ~ 2:30 amDr. Dariush Mohammadyani
(Johnson and Johnson)
Computational Approach to Drug Delivery of RNA Therapeutics and Vaccines
2:30 am ~ 3:00 amDr. Chandrashekhar Kulkarni
(Lipid Nanostructures Laboratory at the University of Central Lancashire:UCLan)
NanoStructure Softmaterials as Drug Delivery Systems
3:00 am ~ 3:30 amDr. Firas Al-Zubaydi
(University of Baghdad)
Liposomal Doxorubicin to Lipid Nanoparticles: Improvement in Science from the Past to Future
4:00 am ~ 4:30 amDr. Aniket Mahapure
(Harvard University)
Synthesizing Lipids from Research to Commercial
4:30 am ~ 5:00 amDr. Jayachandra Babu Ramapuram
(Auburn University)
Solubility Improvements for Transdermal and Oral Delivery of Pharmaceutical
5:00 am ~5:30 amDr. Vivek Gupta
(PulmoSIM Therapeutics, St. John University)
Pharmaceutical Research Overview: Cancer Research, Pulmonology and In Vitro
6:00 am ~6:30 amFormulations Round Table
(T&T Scientific Corp)
Day Recap, Key points, Question and Answers (Q&A) from Formulation Experts and Open Discussions
6:30 am ~7:00 amVirtual Reception Opportunity for Virtual Networking with Cooperation Potentials, Job Opportunities, and Making Connection for Any Assistant in the Field of Drug Delivery(Time to Grab a Drink if You Can and Like; and chat with colleagues)

二日目:8月6日(金)プログラム

テーマ:Drug Delivery Systems Complexed with Active Pharmaceutical Ingredients

時 刻
(日本時間)
演 者
(所 属)
演 題
12:00 am ~ 1:00 am
(Keynote Speech:基調講演)
Dr. Michael McCaman
(BDO-USA)
Lipid Nanoparticle Gene Therapies and Vaccines: from Development to Manufacturing
1:30 am ~ 2:00 amDr. Valerio Pereno
(Oxford Nano Imaging:ONI)
Lipid Vesicles Below the Diffraction Limit: A Case Study on Imaging Extracellular Vesicles with Super-Resolution Microscopy
2:00 am ~ 2:30 amDr. Eshu Middha
(LuminiCell)
Lipid Based Aggregation-Induced Emission (AIE) Nanocarriers for Effective Nucleic Acid Delivery
2:30 am ~ 3:00 amDr. Laila Kudsiova
(School of Pharmacy - Centre for Regenerative Medicine)
Novel Lipopolyplex and Lipid-based Gene Delivery Vectors for DNA and siRNA
3:00 am ~ 3:30 amDr. Rohidas Arote
(Seoul National University)
Biomaterials, Nanobiotechnology and NanomedicineS for Gene therapy, Drug Delivery Applications for Cancer, Neurodegenerative Diseases
4:00 am ~ 4:30 amDr. Hardik Amin
(University of Montana)
Opioid and Flu Vaccine Formulation for Clinical Development
5:00 am ~5:30 amDr. Jayesh Kulkarni
(NanoMedicines Innovation Network:NMIN)
Lipid-based Drug Delivery Systems for Small Molecule Therapeutics, Proteins, and Genetic
6:00 am ~6:30 amPharmaceutical Vaccines and Therapeutics Round Table
(T&T Scientific Corp)
Day Recap, Key points, Question and Answers (Q&A) from Formulation Experts and Open Discussion
6:30 am ~7:00 amVirtual Reception Opportunity for Virtual Networking with Cooperation Potentials, Job Opportunities, and Making Connection for Any Assistant in the Field of Drug Delivery (Time to Grab a Drink if You Can and Like; and chat with colleagues)

三日目:8月7日(土)プログラム

テーマ:Clinical and Commercial Manufacturing Applications of Non-viral Based Nanoparticle Vaccines and Therapeutics

時 刻
(日本時間)
演 者
(所 属)
演 題
12:00 am ~ 1:00 am
(Keynote Speech:基調講演)
Mr. Greg Troiano
(Translate Bio)
Overcoming Challenges of Clinical and Commercial Supply Chain for Complex Nanoparticle Formulations
1:30 am ~ 2:00 amMs. May Guo
(Tri-link Biotechnologies)
Enabling mRNA for Vaccines and Therapeutics
2:00 am ~ 2:30 amMr. Arun Kedia
(Vav Life Sciences)
Global Lipid Supply Chain for Lipid Based Therapeutics and Vaccines
2:30 am ~ 3:00 amMr. Dave Moore
(Toralgen)
Pharmaceutical Leadership in Formulation and Manufacturing Supply Chain
3:00 am ~ 3:30 amMr. Alex Aust, MS, MBA
(T&T Scientific Corp.)
Lipid Nanoparticle Pharmaceuticals Overview: Technologies, Quality Assurance, Manufacturing Processes, Supply Chains
4:00 am ~ 4:30 amDr. Bruce Ramshaw, MD
(CQ Insight)
Value-Based Innovation for The Future of Healthcare in The Real World: The Paradigm for a Sustainable Healthcare System
4:30 am ~ 5:00 amDr. Rajesh Krishnan
(Providence Therapeutics)
mRNA Lipid Nanoparticle Vaccines: from Concept to Patient
5:00 am ~5:30 amMr. Gerald W. Rea
(Toralgen Therapeutics)
Pharmaceutical Ventures and Funding Allocations and Distributions
6:00 am ~6:30 amClinical and Commercial Manufacturing Round Table
(T&T Scientific Corp)
Day Recap, Key points, Question and Answers (Q&A) from Formulation Experts and Open Discussions
6:30 am ~7:00 amVirtual Reception Opportunity for Virtual Networking with Cooperation Potentials, Job Opportunities, and Making Connection for Any Assistant in the Field of Drug Delivery (Time to Grab a Drink if You Can and Like; and chat with colleagues)

演者一覧

演 者略 歴
Dr. Gaurav Sahay

Dr. Gaurav Sahay

Dr. Sahay's lab at Oregon State University is developing novel nanotechnology-based platforms including lipid-based nanoparticles for effective delivery of messenger RNA therapeutics for treatment of cystic fibrosis, retinal degeneration and against SARS-CoV2. He has done pioneering work to dissect the intracellular transport essential for nucleic acid delivery to the cytosol and developed methods to overcome endosomal barriers. He has more than 48-peer-reviewed publications in top tier journals including Science Advances, Nature, Nature Communications, Nature Biotechnology, Nature Nanotechnology, Journal of Controlled Release, Nano Letters etc.
Dr. Michael McCaman

Dr. Michael McCaman

Dr. Michael McCaman is a scientist and a biotechnology leader with a wealth of experience in pharmaceutical nanoparticles from the formulation to CMC and commercial manufacturing at Lonza, Halozyme Therapeutics, and Intellia. He is certainly one of the world's top scientists and industry leader with the focus on the lipid nanoparticle biologics, biological therapeutic platforms including proteins, antibodies, engineered virus, and human cellular therapies. He is currently a senior consultant at BDO.

In the manufacturing space, Dr. McCaman has led several technical projects and managed protein and lipid based therapeutics, viral/plasmid gene therapy, and cell therapy (stem cell and allogeneic) products.

As a Scientist Dr. McCaman has over 25 journal publications and is an author and editor of biotechnology books.
Mr. Greg Troiano

Mr. Greg Troiano

Mr. Troiano is a world's top experienced manufacturing operations executive who has led the development of pharmaceutical products from feasibility through commercial production. Mr. Troiano is now leading cGMP CMC operations at Translate Bio, including clinical supply, analytical testing, quality and engineering. Previously, he was VP of Technology and Chief Engineer at Seer. He was also VP of Nanomedicine Development and Manufacturing within Pfizer's Pharmaceutical Sciences leading the development and manufacturing of novel nanoparticle drug products. With over 20 years of experience in various level of biopharmaceutical manufacturing procecess, Mr. Troiano supported the technical operations behind the commercialization of Gliadel® Wafer, Nutropin Depot®, Risperdal Consta®, Vivitrol® and Bydureon®
Dr. Laila Kudsiova

Dr. Laila Kudsiova

Dr. Laila Kudsiova is a Senior Lecturer at the School of Pharmacy and Biomolecular Sciences at the Centre for Stress and Age-Related Disease and Centre for Regenerative Medicine.

Dr. Kudsiova research focuses in improving the delivery of drugs and large therapeutic molecules such as DNA and siRNA for the treatment of incurable diseases such as genetic disorders and cancer, through designing and developing novel non-viral gene delivery vectors and understanding their interactions with cellular membranes. Her recent study involved the administration of such vectors to the brain via convection enhanced delivery (CED) for the treatment of neurodegenerative diseases.
Dr. Dariush Mohammadyani

Dr. Dariush Mohammadyani

Dr. Dariush Mohammadyani is a senior scientist at Johnson and Johnson. He utilizes state-of-the-art computational approaches to analyze data and model biologics drugs. Previously, Dariush worked at Moderna Therapeutics, where for the first time, he modeled lipid nanoparticles containing RNA. During his postdoctoral fellow programs in the Department of Biophysics at Johns Hopkins University. His research has been centered on computational biophysics and computational structural biology. He received his Ph.D. from the University of Pittsburgh, Department of Bioengineering (2016). He is a co-author of more than 20 peer-reviewed journal papers, such as Nature Communications, Nature Cell Biology, Nature Chemistry, and Science Signaling.
Ms. May Guo

Ms. May Guo

May is the Director of Business Development at TriLink, responsible for customers on the East Coast. She has over 15 years of experience supporting the scientists in drug discovery, genomic research and cellular analysis. Prior to TriLink, May worked for Promega, Agilent and Synthego. She is well versed in the drug discovery process and molecular techniques. Her goal is to help customers to accelerate their mRNA clinical programs. May received her bachelor's degree in Chemistry from Peking University and MBA from Georgetown University.
Mr. Dave Moore

Mr. Dave Moore

Mr. Moore is a decisive leader committed to providing clarity to complex business problems in pharmaceutical industry. Strong track record of building and motivating diverse teams to achieve challenging objectives. Ability to work across multiple functions to create alignment and provide clarity to complex business problems. Proven experience in reshaping organizations to find new ways to uncover market opportunities, improve customer experiences and drive business results. Dave specialties are strategic planning, coaching and development, organizational redesign, building a high performing team, global brand development, uncovering deep customer insights, competitive/business intelligence, and creating organizational alignments.
Dr. Chandrashekhar Kulkarni

Dr. Chandrashekhar Kulkarni

Dr. Chandrashekhar is currently leading a Lipid Nanostructures Laboratory at the University of Central Lancashire (UCLan). Earlier, he worked as a postdoc at the University of Cambridge (UK), University of Bayreuth (Germany) and University of Graz (Austria). He obtained his PhD in Chemical Biology with a Marie Curie Fellowship (2005-2008) hosted by Imperial College London (UK). His main research interests include lipid nanostructures (self-assembly), model biomembranes, drug nanocarriers, hybrid (soft/bio) nanomaterials and hierarchically ordered materials.
Dr. Jayesh Kulkarni

Dr. Jayesh Kulkarni

Dr. Kulkarni is a nanomedicine scientist with academic and industry experience in the field of lipid-based drug delivery systems for small molecule therapeutics, proteins, and genetic drugs. As a researcher, he has made major contributions in the design and development of lipid nanoparticles (LNP). Most notably, my work has described the biophysical processes of LNP formation, the mechanism by which these particles form, and the numerous factors that can affect this process. His work has provided the foundational basis for the design and manipulation of particle formation processes to improve LNP potency and prevent deleterious effects of formulation methods.
Dr. Jayachandra Ramapuram

Dr. Jayachandra Ramapuram

Dr. Jayachandra Babu Ramapuram is currently a Professor of Pharmaceutics at the Harrison School of Pharmacy, Auburn University, AL. His research interests include 3D printed implants, nanoparticle-based formulations for topical, transdermal and oral delivery, solubility improvement of insoluble drugs and percutaneous penetration enhancement techniques. He has supervised/supervising 12 graduate students and 4 postdoctoral fellows in his laboratory. He has been funded by federal grants and pharmaceutical companies. He has authored and co-authored 80 peer-reviewed papers research papers and 10 book chapters and presented his research work in 100 posters/oral presentations in several national and international conferences.
Dr. Vivek Gupta

Dr. Vivek Gupta

Dr Vivek Gupta is Co-founder of PulmoSIM Therapeutics and Assistant Professor at St. John's University College of Pharmacy & Health Sciences with a demonstrated history of working in the higher education industry. Dr Gupta is highly experienced and skilled in Pharmaceutical Research, Cancer Research, Pulmonology, Flow Cytometry, and In Vitro. Strong operations professional with a Ph.D. focused in Pharmaceutical Sciences from Texas Tech University Health Sciences Center. His rich experience include working at St. John's University, PulmoSIM Therapeutics Keck Graduate Institute, University of California Santa Barbara.
Dr. Bruce Ramshaw

Dr. Bruce Ramshaw

Dr. Ramshaw is a successful Surgeon who in October 2015 became a professor and the Chair of Surgery University of Tennessee and in 2017 he became an adjunct professor in the graduate and executive MBA program at the Haslam College of Business at UT. In 2019, he became a member of the International Advisory Council for APCO Worldwide.

In January 2021, he committed full-time to managing CQInsights, a Public Benefit Corporation, with his partners Remi Forman and Briana Alvoid-Preston. CQInsights is committed to help transform our global healthcare system from one based on volume to one based on value for the patient. Dr. Ramshaw founded a healthcare data analytics company, now known as CQInsights, to help mature a new model for healthcare based on measuring and improving value for the patient. He served as the President of the Americas Hernia Society in 2013-2014.
Professor Rohidas Arote

Professor Rohidas Arote

Prof. Arote Rohidas received his BS (2000) and MS (2002) in Pharmacy from the University of Pune and University of Mumbai respectively. He worked as Formulation scientist in leading pharmaceutical industry in India before he joined a PhD in South Korea. He completed his Ph.D. in Biotechnology in 2009 as Brain Korea 21 Fellow (2005-2009) from Seoul National University, Republic of Korea. Thereafter, he worked as postdoctoral research associate in Institute of Agriculture and Life Sciences of College of Agriculture and Life Sciences at Seoul National University, South Korea. From December 2010 he moved to School of Dentistry, Department of Molecular Genetics, Seoul National University as an Assistant Professor. Prof. Arote explored the field of biomaterials, nanobiotechnology and nanomedicine for gene therapy, drug delivery applications for cancer, neurodegenerative diseases and inflammatory bowel diseases. Currently, Prof. Arote is working as an Associate Professor in the Department of Molecular Genetics and Dental Research Institute, School of Dentistry, Seoul National University and his research group is pursuing various nanomedicine research projects aimed at developing advanced nanomaterials for gene therapy applications and nanoparticles-based drug delivery systems (DDS) for treatment of cancer, neurodegenerative disorders and also using nanoparticles for imaging and theranostics.
Dr. Richard (Trey) Fisher

Dr. Richard (Trey) Fisher

Dr. Trey Fisher, a formulation technology inventor and scientist, is the Director of Formulations at T&T Scientific. Dr. Fisher has extensive experience and focused expertise on non-viral drug delivery platforms for nucleic acids. His first notable invention was the discovery of a novel, scalable Lipid Nanoparticle (LNP) formulation for the encapsulation of nucleic acids for gene therapy and mRNA vaccine applications. He is well known for formulating lipid nanoparticles for wide range of Active Pharmaceutical Ingredients including RNA, proteins, peptides, antibodies, small and large molecules. Dr. Fisher and his team uses neutral, cationic, and ionizable lipids to build a library of lipid nanoparticle formulations at T&T Scientific.
Dr. Hardik Amin

Dr. Hardik Amin

Dr. Hardik Amin is an experienced drug delivery and formulation development scientist who worked at the National Institute of Health (NIH) at the National Cancer Institute (NCI). He is currently a Postdoctoral Scientist at the Center for Translational Medicine, University of Montana. Hardik's current research focuses on Opioid and Flu vaccine formulation for clinical development, taking molecules from drug discovery to the development phase, working with a GSK team, collaborators, and a start-up. Hardik's past research focus has been on cancer targeting, breast cancer metastasis, tumor microenvironment, delivery to the brain, bio-therapeutics delivery, and immunotherapy.
Dr. Eshu Middha

Dr. Eshu Middha

Dr. Eshu Middha is the Chief Scientific Officer of Luminicell Pte Ltd, which is a Singapore-based biotech spinoff that specialises in the development and manufacturing of fluorescent based lipid nanoparticles. He is a PhD graduate from the Department of Chemical and Biomolecular Engineering, NUS. He has expertise of more than 6 years in making high-quality organic nanocarriers for sensing, imaging and therapeutic applications. He is specialized in the fabrication of microfluidics devices for the synthesis of superior lipid nanocarriers. Currently, he is working on the development of highly sensitive fluorescent-based lateral flow immunoassay kits for the detection of viral and bacterial diseases.
Dr. Aniket Mahapure

Dr. Aniket Mahapure

Dr. Aniket Mahapure is a Harvard University Scholar with experience demonstrated a history of working in the higher education industry. Dr Mahapure has wealth of experience in pharmaceutical CMC industry, lipid chemistry, materials science, spectroscopy, organic chemistry.
Dr. Gaurav Sahay

Dr. Gaurav Sahay

Dr. Valerio Pereno's background spans the biomedical engineering and drug delivery fields, with specific experience in ultrasound-mediated delivery of therapeutics to solid tumors.

As part of the Business Development team at ONI, he focuses on investigating novel applications and establishing strategic partnerships across different fields. Valerio completed his DPhil and MSc at the University of Oxford and received an MEng in Mechatronics and AKC from King's College London.
Dr. Firas Al-Zubaydi

Dr. Firas Al-Zubaydi

Professor Firas Al-Zubaydi's background is extensive work on polymer based liposomal doxorubicin for treatment of breast cancer, research that was done at the University of Rutgers. Dr. Al-Zubaydi has a vast experience on non-viral lipid and polymer based nanoparticles for delivery of toxic therapeutics as he started his lab as a professor at the University of Baghdad.
Dr. Rajesh Krishnan

Dr. Rajesh Krishnan

Dr. Krishnan has a PhD in organic chemistry. I have been working with formulation development for the last ten years with focus on nucleic acid delivery. Currently is the Director of Formulations for Providence Therapeutics and working with LNP mRNA vaccines. His experience and expertise spread from R&D to GMP manufacturing.
Mr. Arun Kedia

Mr. Arun Kedia

Mr. Arun Kedia is a Chemical Engineer by education, admired in the Indian and International corporates as an entrepreneur with expertise in manufacturing lipids and lipid derivatives for nanotechnology. He has dedicated three decades to research and explore innovative aspects of lecithins & phospholipids as a service towards various healthcare segments including Pharmaceuticals, Nutraceuticals & Cosmetics. He is an active contributor in several reference books like Handbook of Pharmaceutical Excipients. He has been a member of core research groups such as Phospholipid Research Centre and International Lecithins & Phospholipids Society. Currently, he is the founder Director of VAV group established in 2003 with a modest initial capital. Today VAV is recognised as a significant player in the global phospholipid market with a WHO GMP approved manufacturing facility in Ratnagiri, India. VAV is a pioneer for natural and synthetic phospholipids in Indian market.
Alex Aust, MS, MBA

Mr. Alex Aust, MS, MBA
(Conference Chairmen)

Mr. Alex Aust, the Director of Business Development at T&T Scientific has strong talent, experience and knowledge of the industry that will bring you the true value from the project preparation, guidance, and proposal execution to completion of all deliverables for your drug products, whether it is in the discovery stage or commercial GMP manufacturing, and of course, anything in between. Alex has experience executing over 20 RNA technology transfers development and manufacturing projects with lipid-based formulations.

Alex Aust, the Director of Business Development, has vast experience in complex formulations, liquid injectables, and Lipid Nanoparticle (LNP) pharmaceutical manufacturing. His experience includes drug chemistry, analytics, manufacturing, and Controls (CMC), Business Development (BD), Supply Chain, Strategic Planning, Master Scheduling, Marketing, Quality Assurance, Validation Engineering, Quality Control, and Technical Writing as well as Regulatory in the pharmaceutical industry. Specifically, his background is in manufacturing nanoparticles and lipid-based drug delivery systems (lipid nanoparticles (LNP), liposomes, suspensions, etc.).

Alex joined T&T Scientific after spending about 10 years at a world-leading pharmaceutical liquid and complex drug injectable manufacturing. His experience and knowledge of the industry will bring you the true value from the project preparation, guidance, and proposal execution to completion of all deliverables for your drug products, whether it is in the discovery stage or commercial GMP manufacturing, and of course, anything in between.

Alex earned his M.B.A from Ball State University with a concentration on Manufacturing and Production Management. Previous to this, he obtained an M.S. from Purdue University while studying Molecular and Cellular Biology; his undergraduate studies were completed at the University of Southern Indiana; where he majored in Biology and minored in History.
Dr. Nima Tamaddoni

Dr. Nima Tamaddoni
(Conference Chairmen)

Dr. Nima Tamaddoni, the Chief Executive Officer at T&T Scientific Corp., is a business executive, scientist, and co-creator of T&T Scientific University with solid support for practical and applied learning experience within a company. Nima strongly believes that the future of academia and academic research will stem from companies where the research directly impacts human well-being. Therefore, he has initiated this effort through the T&T Scientific University. T&T Scientific University is built with a vision of having all research and eductions to be performed in companies. With this vision, we hope to maximize the transition of precious basic research to real-world application seamlessly with incredibly talented scientists who currently work in academia.

Dr. Tamaddoni has over ten years of academic, industrial, and business experience focused on lipid nanoparticles and liposomes. With leadership and engineering skills, knowledge, and training, he has successfully led the business growth and multiple pharmaceuticals research, development, and manufacturing projects at T&T Scientific Corporation. His goal at T&T Scientific is to help develop and improve technologies that increase the efficiency of translating promising medical technology from research and development to scaled-up pharmaceutical manufacturing for clinical trials and approved patient use. Nima's industry experience has been managing custom development and manufacturing non-viral delivery technologies for various pharmaceutical customers, and several projects have required working remotely and on-site with top-tier pharmaceutical companies.

Since founding T&T Scientific, he has managed intra-company global business development projects to develop and improve tools that accelerate liposome and lipid nanoparticle-related and other non-viral vector research, development, and manufacturing. He helped lead the successful development and launch of multiple products in our NanoSizer product line, which provides scalable options for a cleaner, faster, and easier low-cost production of liposomes and lipid nanoparticles. Researchers and pharmaceutical manufacturers are using T&T NanoSizer devices in academia and industry in over 60 countries. We are expanding our product portfolio with a continuous solvent injection and exchange technology called NanoSizer FLOW. Twelve patents and three trademarks protect T&T Scientific's technologies.
Mr. Gerald Rea

Mr. Gerald Rea

Gerald W. Rea is the Chief Executive Officer of Toralgen, Inc. Toralgen develops novel pharmaceuticals using a breakthrough, oral, drug delivery platform. Toralgen currently focuses on oral insulin and treatments for autoimmune diseases.

Rea began his career at Rose-Hulman Ventures designing medical equipment and optical sensors. He was previously the CEO of Stray Light Optical Technologies. Stray Light, with Sandia National Labs, received the Top Technology Transfer Award from the Federal Laboratories Consortium in 2012. While leading Stray Light, he participated in the Academy Awards, last NASA manned shuttle launch, and various DoD projects. He has been collaborating with Dr. Fahmy at Yale University since 2014 to develop and commercialize novel pharmaceutical nanoplatforms. He is a Distinguished Alumni from Rose-Hulman Institute of Technology with degrees in Optical and Mechanical engineering.


目次に戻る

お問い合わせ先

(テクニカルサポート 機器・消耗品担当)

kiki@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。